Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.32 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.31 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.31 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.31 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.31 |
| ▸ | PYGL | P06737 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14328427 | 1.00 | TSHR (0.33) | TSHRCHRM5CHRM1CHRM3CHRM2 | |
| SCHEMBL18850030 | 1.00 | TSHR (0.33) | TSHRCHRM5CHRM1CHRM3CHRM2 | |
| SCHEMBL6933813 | 1.00 | TSHR (0.33) | TSHRCHRM5CHRM1CHRM3CHRM2 | |
| SCHEMBL24520605 | 1.00 | TSHR (0.33) | TSHRCHRM5CHRM1CHRM3CHRM2 | |
| SCHEMBL12522349 | 1.00 | TSHR (0.33) | TSHRCHRM5CHRM1CHRM3CHRM2 | |
| SCHEMBL24943522 | 1.00 | TSHR (0.33) | TSHRCHRM5CHRM1CHRM3CHRM2 | |
| SCHEMBL6932362 | 1.00 | TSHR (0.33) | TSHRCHRM5CHRM1CHRM3CHRM2 | |
| SCHEMBL21370154 | 1.00 | TSHR (0.33) | TSHRCHRM5CHRM1CHRM3CHRM2 | |
| SCHEMBL22045699 | 1.00 | TSHR (0.33) | TSHRCHRM5CHRM1CHRM3CHRM2 | |
| SCHEMBL18349326 | 1.00 | TSHR (0.33) | TSHRCHRM5CHRM1CHRM3CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118291457-A | Nucleic acid, composition containing nucleic acid, conjugate, preparation method and application | 苏州瑞博生物技术股份有限公司 | 2024-07-05 | — | — | CN | claimed |
| CN-118291456-A | Nucleic acid, composition containing nucleic acid, conjugate, preparation method and application | 苏州瑞博生物技术股份有限公司 | 2024-07-05 | — | — | CN | claimed |
| CN-118256498-A | Nucleic acid, pharmaceutical composition and conjugate, and preparation method and application thereof | 苏州瑞博生物技术股份有限公司 | 2024-06-28 | — | — | CN | claimed |
| CN-118252843-A | Nucleic acid, pharmaceutical composition and conjugate, and preparation method and application thereof | 苏州瑞博生物技术股份有限公司 | 2024-06-28 | — | — | CN | claimed |
| CN-118217305-A | Nucleic acid, pharmaceutical composition and conjugate, and preparation method and application thereof | 苏州瑞博生物技术股份有限公司 | 2024-06-21 | — | — | CN | claimed |
| CN-118475356-A | Drug conjugates of saccharide derivatives and their use as senescent cell lysing agents | 鲁贝多生命科学公司 | 2024-08-09 | — | — | CN | disclosed |
| CN-113286888-B | Nucleic acid, pharmaceutical composition and conjugate, and preparation method and application thereof | 苏州瑞博生物技术股份有限公司 | 2023-12-22 | — | — | CN | disclosed |
| US-20230138729-A1 | Coumarin Derivatives of Sugar Analogs and Uses Thereof | Rubedo Life Sciences, Inc. | 2023-05-04 | — | — | US | disclosed |
| US-20230138729-A1 | Coumarin Derivatives of Sugar Analogs and Uses Thereof | Rubedo Life Sciences, Inc. | 2023-05-04 | — | — | US | disclosed |
| US-20230130134-A1 | METHOD OF TREATING VIRAL INFECTIONS WITH HEXOSE TYPE MONOSACCHARIDES AND ANALOGS THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-04-27 | — | — | US | disclosed |
| EP-4121060-A1 | METHOD OF TREATING VIRAL INFECTIONS WITH HEXOSE TYPE MONOSACCHARIDES AND ANALOGS THEREOF | Board of Regents, The University of Texas System (US) | 2023-01-25 | — | — | EP | disclosed |
| CN-115515601-A | Methods of treating viral infections with hexose-type monosaccharides and analogs thereof | 得克萨斯大学体系董事会 | 2022-12-23 | — | — | CN | disclosed |
| WO-2012097052-A2 | MONOSACCHARIDE-BASED COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE AND INFLAMMATORY DERMATOLOGICAL DISEASES | INTERTECH BIO, LLC (US) | 2012-07-19 | — | — | WO | disclosed |
| EP-2017281-A1 | TOLL-LIKE RECEPTOR 9 AGONISTS | Kyowa Hakko Kirin Co., Ltd. (JP) | 2009-01-21 | — | — | EP | disclosed |
| US-20040024196-A1 | Phase transfer catalyzed glycosidation of an indolocarbazole | PETRILLO DANIEL E (US) | 2004-02-05 | — | — | US | disclosed |
| EP-1333826-A2 | PHASE TRANSFER CATALYZED GLYCOSIDATION OF AN INDOLOCARBAZOLE | Merck & Co., Inc. (US) | 2003-08-13 | — | — | EP | disclosed |
| US-6555677-B2 | Preparing preferential compound; incubate sugar with activating agent, couple activated sugar with preferential compound, recover compound | MERCK & CO., INC. | 2003-04-29 | — | — | US | disclosed |
| US-20020058803-A1 | Phase transfer catalyzed glycosidation of an indolocarbazole | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-05-16 | — | — | US | disclosed |
| WO-2002036601-A2 | PHASE TRANSFER CATALYZED GLYCOSIDATION OF AN INDOLOCARBAZOLE | MERCK & CO., INC. (US) | 2002-05-10 | — | — | WO | disclosed |
| WO-1993017032-A1 | TECHNIQUES AND INTERMEDIATES FOR PREPARING NON-PEPTIDE PEPTIDOMIMETICS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1993-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024196-A1 | Phase transfer catalyzed glycosidation of an indolocarbazole | UGGT1, UGCG, GPI | TSHR 2347/4885CHRM5 4775/4885CHRM1 4732/4885 |
| US-20230138729-A1 | Coumarin Derivatives of Sugar Analogs and Uses Thereof | GLA, ENGASE, GLB1 | TSHR 3564/4885CHRM5 2889/4885CHRM1 2523/4885 |
| US-20020058803-A1 | Phase transfer catalyzed glycosidation of an indolocarbazole | UGGT1, UGCG, GPI | TSHR 2347/4885CHRM5 4775/4885CHRM1 4732/4885 |
| US-20230130134-A1 | METHOD OF TREATING VIRAL INFECTIONS WITH HEXOSE TYPE MONOSACCHARIDES AND ANALOGS THEREOF | G6PD, FBP1, ALDOA | TSHR 3732/4885CHRM5 4276/4885CHRM1 4401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.